UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech innovator focused on developing and commercializing therapies for urothelial and specialty cancers, will present at the TD Cowen 46th Annual Health Care Conference scheduled for March 2-4, 2026. The company's management is set to deliver their presentation on March 3, 2026, at 1:50 PM ET, in Boston, MA. Attendees can access the presentation and subsequent 1x1 investor meetings, with a live webcast available on UroGen’s corporate website for those unable to attend in person; a replay will be accessible for 30 days thereafter.

UroGen Pharma is committed to providing improved treatment options for patients with urothelial cancers through its innovative technologies. A key facet of its approach is the proprietary RTGel® reverse-thermal hydrogel platform, designed to enhance the efficacy of existing medications by enabling sustained release within the urinary tract. This technology aims to facilitate more effective local therapies, thereby prolonging the therapeutic exposure of medication to affected tissues.

The company’s lead product is already approved for the treatment of low-grade upper tract urothelial cancer, while their second product holds the distinction of being the first and only FDA-approved treatment for adult patients facing recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both products utilize non-surgical methods to ablate tumors, placing UroGen Pharma at the forefront of innovative cancer treatments.

UroGen operates out of Princeton, NJ, and has a presence in Israel. Interested parties can learn more about UroGen Pharma's initiatives by visiting their official website or connecting via social media platforms such as Twitter. For investor inquiries, Vincent Perrone and Cindy Romano are available for further communication.

As UroGen Pharma Ltd. prepares for its presentation at the TD Cowen 46th Annual Health Care Conference, investors should consider several key points that could impact the stock's performance. The company specializes in innovative solutions for treating urothelial and specialty cancers, an area with significant medical need and a growing market presence.

UroGen's proprietary RTGel® technology allows for sustained drug release, a potential game-changer in local therapies aimed at the urinary tract. Their unique approach not only enhances the efficacy of existing medications but also reduces the need for invasive procedures, making it an attractive option for both patients and healthcare providers. Investors should pay close attention to any announcements regarding clinical trial results or collaboration opportunities during the conference, as this could influence market sentiment and stock performance.

UroGen's current portfolio includes two FDA-approved products focused on low-grade upper tract urothelial cancer and non-muscle invasive bladder cancer. Any updates regarding sales performance or new indications for these drugs could be critical. If management highlights positive reception from the medical community or successful patient outcomes, it may bolster investor confidence.

Moreover, the biotech sector is sensitive to regulatory developments, and UroGen's pipeline expansion could signal future growth potential. Investors should monitor for updates on any ongoing trials and the timeline for potential new product approvals.

Overall, UroGen presents a compelling growth story in the biotech space, especially given its innovative approach to cancer treatment. However, due diligence is crucial—investors must weigh the potential rewards against the inherent risks associated with biotech investments, including regulatory hurdles and market competition.